← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Avantgen, Inc.
San Diego, CA
$14,988,529
Total funding
23
Grants
Funding over time
peak $2.1M · FY2008–25$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,988,529 · 23
By mechanism
N44$6,996,000 · 6
R44$3,759,778 · 2
R43$1,984,187 · 7
N43$1,948,710 · 7
N01$299,854 · 1
Investigators at Avantgen, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development and validation of anti-canine reagents to enable pre-clinical development of novel therapeutics$1,995,852
N44 · FY2020 · CA
Development of rabbit monoclonal antibodies for Ferret biomarkers (Phase II)$1,497,384
N44 · FY2025 · AI
A novel approach for treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)$1,398,552
R44 · FY2024 · CA
IGF::OT::IGF RECOMBINANT RABBIT MONOCLONAL ANTIBODIES AS AFFINITY CAPTURES FOR PEPTIDES$999,996
N44 · FY2015 · CA
OTHER FUNCTIONS - RECOMBINANT ANTIBODIES AS AFFINITY CAPTURES$990,779
N44 · FY2012 · HL
Novel approach for developing antibody reagents to probe changes in the synapse p$805,808
R44 · FY2016 · DA
Novel approach for developing antibody reagents to probe changes in the synapse p$756,189
R44 · FY2015 · DA
TAS::75 0893::TAS RENEWABLE CAPTURES FOR ADDICTION-RELEVANT PROTEINS$750,000
N44 · FY2010 · DA
OTHER FUNCTIONS SBIR PHASE II, TOPIC 288, "RECOMBINANT ANTIBODIES AS AFFINITY CA$747,441
N44 · FY2012 · CA
DEVELOPMENT OF RABBITMONOCLONAL ANTIBODIES FOR INDIANFLYING FOX (BAT) BIOMARKERS$592,751
N43 · FY2024 · AI
A novel approach for treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)$574,272
R44 · FY2025 · CA
DEVELOPMENT OF RABBIT MONOCLONAL ANTIBODIES FOR FERRET BIOMARKERS$356,021
N43 · FY2021 · AI
A novel approach for developing GPCR subtype specific antibodies$349,719
R43 · FY2011 · MH
A novel approach for developing GPCR subtype specific antibodies$341,965
R43 · FY2012 · MH
DEVELOPMENT OF RAPID POINT-OF-CARE DIAGNOSTICS FOR HEPATITIS C VIRUS$300,000
N43 · FY2021 · AI
IGF::OT::IGF Topic 372 - SBIR Phase I: Development and Validation of Non- Mouse Reagents to Enable Preclinical Development of Novel Therapeutics - Moonshot$299,854
N01 · FY2018 · CA
Endothelial Lipase: a novel therapeutic target for HDL and atherosclerosis$277,115
R43 · FY2010 · HL
Novel approach for developing antibody reagents to probe changes in the synapse p$224,957
R44 · FY2013 · DA
Developing a highly specific and sensitive glucagon ELISA kit$224,670
R43 · FY2015 · DK
Discovery of novel Alzheimer's Disease-specific antigens/epitopes and their captu$224,528
R43 · FY2014 · AG